IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Novo says Wegovy trial moved 40% of young children out of obesity — Sep 7, 2026In Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.

Chris Dalton Glad there's finally something beyond diet and exercise lectures for kids who genuinely struggle, this could change a lot of families' lives.

GLP-1 obesity drugs linked to fewer alcohol hospitalizationsHealth — Jul 21, 2026A multi-trial analysis of about 40,700 adults found GLP-1 receptor agonists such as semaglutide and tirzepatide are associated with substantially lower alcohol-related hospital admissions across diabetics, obesity, and alcohol-use disorder groups, with reductions ranging from roughly 26% to 65% depending on the comparison. Experts say the findings hint at a potential role for these weight‑loss and diabetes drugs in treating alcohol-use disorders, though more research is needed to confirm causality and guide use.